ARS Pharmaceuticals (SPRY) News Today

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is facing renewed investor concern after several law firms publicized a securities-fraud class action and urged shareholders to seek lead-plaintiff status by October 5, 2026. The repeated announcements likely contributed to weakness in the stock, which is already trading well below its 50-day and 200-day moving averages.

• Negative Sentiment: Multiple firms, including Rosen Law Firm, Kaplan Fox, Faruqi & Faruqi, and others, are soliciting investors who purchased SPRY shares between March 9 and June 24, 2026, in connection with a securities class action. The litigation creates potential legal costs, reputational risk, and uncertainty for shareholders. Rosen Law Firm class action announcement
• Negative Sentiment: The allegations reportedly focus on whether ARS adequately disclosed the risk that CVS Caremark’s formulary process could delay coverage for neffy until January 2027. A delay could cause the product to miss the summer and back-to-school allergy seasons, potentially weighing on near-term sales expectations. SueWallSt ARS investor alert
• Neutral Sentiment: The October 5 deadline is procedural and does not establish that ARS violated securities laws; the allegations remain unproven. Investors who qualify may seek lead-plaintiff status or participate through the litigation process without upfront legal fees. SBS ARS securities lawsuit announcement

With shares having decreased toward the lower end of their 52-week range, the litigation headlines add to existing investor sensitivity around ARS Pharmaceuticals’ commercial execution and ongoing losses.